BCIQ Profiles

Company Profile Report
1005 Trump Regeneron
BioCentury & Getty Images

Politics, Policy & Law

Trump treatment resurfaces compassionate use quandaries

Oct 6, 2020 | 2:14 AM GMT

President Donald Trump’s treatment with an investigational drug from Regeneron resurfaces long-standing ethical quandaries involving compassionate use and the allocation of scarce drugs.

The REGN-COV2 cocktail from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that the president received last week is still in clinical trials, and outside that, only available for compassionate use. Providing compassionate use to the president is certain to create demand for access to the investigational therapy. 

Compassionate use policy in the U.S. has for decades been clouded by perceptions

Read the full 1009 word article